Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. (NASDAQ: OVID) is a pioneering biopharmaceutical company dedicated to creating transformative medicines for patients and families affected by rare neurological disorders. The company’s primary focus is on developing treatments for conditions such as Angelman syndrome and Fragile X syndrome through its innovative drug candidates, OV101 and OV935.
OV101, Ovid’s lead drug candidate, is designed to address the symptoms of Angelman syndrome and Fragile X syndrome. The company has initiated the Phase 2 STARS trial to evaluate the efficacy of OV101 in adults with Angelman syndrome and is also conducting a Phase 1 trial in adolescents to identify suitable doses for younger patients. These efforts underscore Ovid’s commitment to advancing treatments for underserved communities.
In collaboration with Takeda Pharmaceutical Company Limited, Ovid is developing OV935 for the treatment of rare epileptic encephalopathies. This partnership aims to leverage both companies' strengths to accelerate the development of novel therapies. Ovid’s pipeline features a range of potential first-in-class and in-class mechanisms of action, highlighting the company's innovative approach to tackling rare epilepsies and seizure-related neurological disorders.
Ovid Therapeutics is also committed to maintaining transparency and fostering a supportive community. The company’s Community Guidelines, available on their website, outline their dedication to integrity and patient-focused values.
Recent corporate updates include the announcement of fourth-quarter and annual 2023 financial results and the first-quarter 2024 financial results, which provide insights into the company’s financial health and strategic direction. Ovid continues to make significant strides in its clinical and research pipeline, aiming to bring meaningful change to the lives of those affected by rare neurological disorders.
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on epilepsy treatments, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Management aims to highlight their innovative therapies and ongoing research.
An archived replay of the presentation will be available on their website post-event. Ovid's pipeline includes OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures, and OV350, targeting epilepsies. Additionally, Ovid is significantly involved in the soticlestat development, currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, managed by Takeda. For further information about Ovid's initiatives, visit ovidrx.com.
Ovid Therapeutics (NASDAQ: OVID) provided a business update and 2022 financial results, indicating a cash runway into H1 2025. The company reported a revenue of $1.5 million for 2022, a significant decline from $208.4 million in 2021. This decline was due to a one-time payment from Takeda in 2021. Ovid continues to advance its potential next-generation GABA-aminotransferase inhibitor, OV329, which is undergoing a Phase 1 trial, with results expected in H1 2024. Ovid also highlights ongoing collaborations and cost-cutting measures that have helped reduce operating expenses. The company posted a net loss of $54.2 million for 2022, compared to a net income of $122.8 million in 2021.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced its participation in a fireside chat during the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 4:00 p.m. ET. Investors can access a live webcast of the event via the company’s website, with an archived replay available afterward. Ovid focuses on developing medicines for epilepsies and brain disorders, with notable programs including OV329, aimed at treatment-resistant seizures, and OV350, intended for potential epilepsy treatment. The company also has significant interest in soticlestat, currently in Phase 3 trials targeting Dravet and Lennox-Gastaut syndromes.
Ovid Therapeutics (NASDAQ: OVID) has published findings regarding its compound OV350 in Cell Reports Medicine, highlighting its potential in treating treatment-resistant epilepsies. OV350 directly activates the KCC2 co-transporter, reducing neuronal hyperexcitability and intracellular chloride accumulation. Preclinical studies reveal that OV350 can arrest benzodiazepine-resistant seizures, restore efficacy of benzodiazepines, and reduce neuronal injury following status epilepticus. The compound was found to penetrate the brain effectively without causing sedation. Ovid aims to explore various modes of delivery for OV350 and other KCC2 activators.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced participation in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 12:50 p.m. ET in Boston, Massachusetts. A live webcast will be available on their website, with an archived replay following the event.
Ovid specializes in biopharmaceuticals aimed at treating epilepsies and brain disorders. Their development pipeline includes OV329 for treatment-resistant seizures and OV350 targeting the KCC2 transporter. They also hold a financial interest in soticlestat, currently in Phase 3 trials, which is being developed by Takeda.
Ovid Therapeutics Inc. (NASDAQ: OVID) announces the appointment of Manoj Malhotra, M.D., as Chief Medical Officer and Toshiya Nishi, D.V.M., as Head of Epilepsy Research. Dr. Malhotra brings extensive experience in neurological medicine and has held senior roles at major pharmaceutical companies. He aims to enhance Ovid’s research pipeline for seizure treatments. Dr. Nishi, co-inventor of soticlestat, will focus on Ovid’s KCC2 transporter activators. Both leaders are expected to play critical roles in advancing Ovid’s innovative therapies for epilepsy, showcasing the company’s commitment to improving the lives of those affected by brain disorders.
Ovid Therapeutics has initiated a Phase 1 study for OV329, a next-generation GABA-aminotransferase inhibitor, aimed at treating rare epilepsies. This first-in-human trial, conducted at Duke University, will assess the safety and efficacy of OV329 in healthy volunteers. The study's design includes single and multiple ascending doses. With over 60 participants expected, results are anticipated in the first half of 2024. This innovative treatment targets treatment-resistant seizures, potentially offering improved safety and efficacy compared to existing medications.
Ovid Therapeutics announced promising preclinical data for OV329 and OV350 at the 2022 American Epilepsy Society Annual Meeting. OV329, a next-generation GABA-aminotransferase inhibitor, showed potential efficacy and safety with low, chronic dosing, outperforming existing treatments. OV350 demonstrated efficacy in activating KCC2 to combat refractory status epilepticus and reduce neuronal damage. Both programs aim to address treatment-resistant epilepsies, providing hope for patients. Key data from NIH's Epilepsy Therapy Screening Program highlighted significant seizure protection in animal models.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
What is the focus of Ovid Therapeutics Inc.?
What are the main drug candidates of Ovid Therapeutics?
What is the purpose of the Phase 2 STARS trial?
How is Ovid Therapeutics collaborating with Takeda?
What recent financial updates has Ovid Therapeutics announced?
Where can I find Ovid Therapeutics' Community Guidelines?
What is the significance of OV101 and OV935 in Ovid's pipeline?
Who are the primary beneficiaries of Ovid Therapeutics' medicines?
How does Ovid Therapeutics contribute to the community?
What are the potential impacts of Ovid's clinical trials?
